Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study

Journal of Translational Medicine

Sonia M Davis³  David J Couper³  Prescott G Woodruff^1,10  Ruth Tal-Singer⁹  Mary Beth Scholand^1,12  Stephen I Rennard⁷  Stephen P Peters⁵  Bruce E Miller⁹  Fernando J Martinez⁸  Eric C Kleerup⁴  Richard E Kanner^1,12  Nadia N Hansel²  Meilan K Han⁸  Jeffrey L Curtis^1,11  Stephanie A Christenson^1,10  Eugene R Bleecker⁵  R Graham Barr^1,13  Claire M Doerschuk¹  Elizabeth E Carretta³  Patricia V Basta⁶  Wayne Anderson^1,14  Wanda K O’Neal¹ 

[1] Cystic Fibrosis/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Department of Medicine, School of Medicine; Department of Environmental Health Sciences, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA;Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA;Center for Genomics and Personalized Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA;Biospecimen Processing Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Department of Internal Medicine, Pulmonary, Critical Care, Sleep and Allergy Division, University of Nebraska Medical Center, Omaha, NE, USA;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health Care System, Ann Arbor, MI, USA;Respiratory Therapy Area Unit, GlaxoSmithKline, King of Prussia, PA, USA;Division of Pulmonary, Critical Care, Sleep and Allergy, Department of Medicine and Cardiovascular Research Institute, University of California at San Francisco, San Francisco, CA, USA;Pulmonary and Critical Care Medicine Section, Medical Service, VA Ann Arbor Healthcare, Ann Arbor, MI, USA;Department of Internal Medicine, Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, UT, USA;College of Physicians and Surgeons, Columbia University, New York, NY, USA;Pulmonary and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

关键词: Pilot study;    EDTA plasma;    Serum;    P100 plasma;    Multiplex assays;    Blood analytes;    Biomarkers;    SPIROMICS;    COPD;    Chronic obstructive pulmonary disease;   

Others  :  822214
DOI  :  10.1186/1479-5876-12-9

 received in 2013-12-09, accepted in 2013-12-09,  发布年份 2014

【 摘 要 】

Background

As a part of the longitudinal Chronic Obstructive Pulmonary Disease (COPD) study, Subpopulations and Intermediate Outcome Measures in COPD study (SPIROMICS), blood samples are being collected from 3200 subjects with the goal of identifying blood biomarkers for sub-phenotyping patients and predicting disease progression. To determine the most reliable sample type for measuring specific blood analytes in the cohort, a pilot study was performed from a subset of 24 subjects comparing serum, Ethylenediaminetetraacetic acid (EDTA) plasma, and EDTA plasma with proteinase inhibitors (P100™).

Methods

105 analytes, chosen for potential relevance to COPD, arranged in 12 multiplex and one simplex platform (Myriad-RBM) were evaluated in duplicate from the three sample types from 24 subjects. The reliability coefficient and the coefficient of variation (CV) were calculated. The performance of each analyte and mean analyte levels were evaluated across sample types.

Results

20% of analytes were not consistently detectable in any sample type. Higher reliability and/or smaller CV were determined for 12 analytes in EDTA plasma compared to serum, and for 11 analytes in serum compared to EDTA plasma. While reliability measures were similar for EDTA plasma and P100 plasma for a majority of analytes, CV was modestly increased in P100 plasma for eight analytes. Each analyte within a multiplex produced independent measurement characteristics, complicating selection of sample type for individual multiplexes.

Conclusions

There were notable detectability and measurability differences between serum and plasma. Multiplexing may not be ideal if large reliability differences exist across analytes measured within the multiplex, especially if values differ based on sample type. For some analytes, the large CV should be considered during experimental design, and the use of duplicate and/or triplicate samples may be necessary. These results should prove useful for studies evaluating selection of samples for evaluation of potential blood biomarkers.

【 授权许可】

   
2014 O'Neal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Couper D, LaVange LM, Han M, Barr RG, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG, Rennard S, for the SPIROMICS Research Group: Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS). Thorax 2013. 10.1136/thoraxjnl-2013-203897. Epub ahead of print
• [2]Biancotto A, Feng X, Langweiler M, Young NS, McCoy JP: Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjects. Cytokine 2012, 60:438-446.
• [3]Yu Z, Kastenmuller G, He Y, Belcredi P, Moller G, Prehn C, Mendes J, Wahl S, Roemisch-Margl W, Ceglarek U, Polonikov A, Dahmen N, Prokisch H, Xie L, Li Y, Wichmann HE, Peters A, Kronenberg F, Suhre K, Adamski J, Illig T, Wang-Sattler R: Differences between human plasma and serum metabolite profiles. PLoS ONE 2011, 6:e21230.
• [4]Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G, Chan DW: HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005, 5:3262-3277.
• [5]Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, Selby PJ: Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 2005, 51:1637-1649.
• [6]Golanski J, Pietrucha T, Baj Z, Greger J, Watala C: Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood-various anticoagulants are not equal. Thromb Res 1996, 83:199-216.
• [7]De JW, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V: Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009, 10:52. BioMed Central Full Text
• [8]Mannello F: Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation. Arterioscler Thromb Vasc Biol 2008, 28:611-614.
• [9]Fu Q, Zhu J, Van Eyk JE: Comparison of multiplex immunoassay platforms. Clin Chem 2010, 56:314-318.
• [10]Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA: Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006, 23:312-328.
• [11]Ricos C, Cava F, Garcia-Lario JV, Hernandez A, Iglesias N, Jimenez CV, Minchinela J, Perich C, Simon M, Domenech MV, Alvarez V: The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest 2004, 64:175-184.
• [12]Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005, 3:1894-1904.
• [13]Thrailkill K, Cockrell G, Simpson P, Moreau C, Fowlkes J, Bunn RC: Physiological matrix metalloproteinase (MMP) concentrations: comparison of serum and plasma specimens. Clin Chem Lab Med 2006, 44:503-504.
• [14]Aziz N, Nishanian P, Mitsuyasu R, Detels R, Fahey JL: Variables that affect assays for plasma cytokines and soluble activation markers. Clin Diagn Lab Immunol 1999, 6:89-95.
• [15]Booth NA, Simpson AJ, Croll A, Bennett B, MacGregor IR: Plasminogen activator inhibitor (PAI-1) in plasma and platelets. Br J Haematol 1988, 70:327-333.
• [16]Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 2001, 47:617-623.
• [17]Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, Zelmanovic D, Newland A: Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 2002, 48:891-899.
• [18]Aguilar-Mahecha A, Kuzyk MA, Domanski D, Borchers CH, Basik M: The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS ONE 2012, 7:e38290.
• [19]Randall SA, McKay MJ, Baker MS, Molloy MP: Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics 2010, 10:2050-2056.
• [20]Wildes D, Wells JA: Sampling the N-terminal proteome of human blood. Proc Natl Acad Sci USA 2010, 107:4561-4566.
• [21]Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Mohring T, Schulz-Knappe P: Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 2005, 5:3414-3422.
• [22]Yi J, Kim C, Gelfand CA: Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res 2007, 6:1768-1781.
• [23]Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG: Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA 2013, 309:2353-2361.
• [24]Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agusti A: Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012, 185:1065-1072.
• [25]Gosselink JV, Hayashi S, Elliott WM, Xing L, Chan B, Yang L, Wright C, Sin D, Pare PD, Pierce JA, Pierce RA, Patterson A, Cooper J, Hogg JC: Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181:1329-1335.